Literature DB >> 374019

The concentration of tobramycin in bronchial secretions.

M R Alexander, E M Berglund, J E Kasik, A Fox, W M Chinn.   

Abstract

Fifteen noninfected patients received three consecutive doses of tobramycin (1.7 mg/kg intramuscularly). Serum and bronchial secretions were obtained during bronchoscopy. Microbiologic assay demonstrated that bronchial secretions containing tobramycin produced inappropriately small zone sizes when compared with serum. Also, it was shown that bronchial secretions frequently do achieve therapeutic concentrations of tobramycin at this dosage level and route of administration.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 374019     DOI: 10.1378/chest.75.6.675

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  5 in total

1.  Systemic absorption of endotracheally administered aminoglycosides in seriously ill patients with pneumonia.

Authors:  S S Crosby; W A Edwards; C Brennan; E P Dellinger; L A Bauer
Journal:  Antimicrob Agents Chemother       Date:  1987-06       Impact factor: 5.191

2.  Bronchial secretion levels of amikacin.

Authors:  W L Dull; M R Alexander; J E Kasik
Journal:  Antimicrob Agents Chemother       Date:  1979-12       Impact factor: 5.191

3.  Activities of various beta-lactams and aminoglycosides, alone and in combination, against isolates of Pseudomonas aeruginosa from patients with cystic fibrosis.

Authors:  R K Scribner; M I Marks; A H Weber; M M Tarpay; D F Welch
Journal:  Antimicrob Agents Chemother       Date:  1982-06       Impact factor: 5.191

4.  Pulmonary retention of free and liposome-encapsulated tobramycin after intratracheal administration in uninfected rats and rats infected with Pseudomonas aeruginosa.

Authors:  A Omri; C Beaulac; M Bouhajib; S Montplaisir; M Sharkawi; J Lagacé
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

5.  Tolerability and Pharmacokinetic Evaluation of Inhaled Dry Powder Tobramycin Free Base in Non-Cystic Fibrosis Bronchiectasis Patients.

Authors:  Marcel Hoppentocht; Onno W Akkerman; Paul Hagedoorn; Jan-Willem C Alffenaar; Tjip S van der Werf; Huib A M Kerstjens; Henderik W Frijlink; Anne H de Boer
Journal:  PLoS One       Date:  2016-03-09       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.